



**FOR IMMEDIATE RELEASE**

**International Diabetes Federation participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes**

*The international consortium aims to provide evidence-based classification of hypoglycaemia to achieve better treatments for people living with diabetes*

(Brussels, Belgium, May 2, 2018) – Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find better solutions to alleviate the burden and consequences of hypoglycaemia in diabetes.

Diabetes is a global pandemic, currently affecting around 60 million people in Europe. Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people with diabetes on insulin therapy. Consisting of very low levels of blood glucose, hypoglycaemia can lead to cognitive decline, cardiovascular events and even death.

As much about hypoglycaemia remains unknown, the recently started European research project Hypo-RESOLVE (Hypoglycaemia – Redefining SOLUTIONS for better LiVEs) aims to provide researchers and clinicians with more validated data about the condition by:

- Creating a sustainable clinical database;
- Conducting studies to better understand the underlying mechanisms of hypoglycaemia;
- Conducting a series of statistical analyses to define predictors and consequences of hypoglycaemia;
- Calculating the financial cost in European countries.

“Our mission within Hypo-RESOLVE is to provide an evidence-based classification of hypoglycaemia based on secure data from 100 to 150 recently conducted clinical trials,” explained Dr Bastiaan de Galan, coordinator of Hypo-RESOLVE and internist at the department of Internal Medicine, Radboud university medical center, in the Netherlands. “With this statistical power, we will be able to make valid statements about the glucose thresholds below which hypoglycaemia constitutes a great risk for people living with diabetes.”

Dr Stephen Gough, Global Chief Medical Officer at Novo Nordisk in Denmark and Hypo-RESOLVE project leader added: “This consortium brings together world leaders from the field of diabetes to reduce the burden of hypoglycaemia. Hypo-RESOLVE paves the way for further research on glucose-lowering interventions that will serve people living with diabetes, clinicians and healthcare companies.”

“Hypoglycaemia remains the most pressing concern of all individuals living with diabetes, particularly insulin requiring diabetes such as type 1 diabetes,” explains Dr Sanjoy Dutta, JDRF Assistant Vice President, Research & International Partnerships. “JDRF is pleased to be an active leader in this large public-private partnership to represent the voices of people affected with this condition, and to collectively understand the causes of and identify solutions to prevent hypoglycaemia.”

**FOR IMMEDIATE RELEASE**

The voices of people living with diabetes will be at the heart of Hypo-RESOLVE, through the establishment of a Patient Advisory Committee. It will ensure that patients’ insights, opinions and wishes are taken into account across all the multiple components of the project.

“Hypoglycaemia presents a huge psychological burden for people with diabetes. We believe that the Patient Advisory Committee will help contribute to a better understanding of the disease’s impact on people with diabetes and ultimately help improve their lives,” said Prof. Nam H. Cho, President of the International Diabetes Federation (IDF). “Through this project, we also hope to strengthen public awareness of hypoglycaemia and diabetes generally.”

Hypo-RESOLVE is supported with funding of € 26.8 million from the Innovative Medicines Initiative (IMI), a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), JDRF, and the Leona M. and Harry B. Helmsley Charitable Trust.

The project will officially kick off its activities with a first meeting in Denmark on May 16-17, 2018.

**Project facts**

**Project acronym:** Hypo-RESOLVE  
**Start date:** 01 May 2018  
**Duration:** 48 months  
**Budget:** € 26.8 Mio  
**Coordination:** Radboud university medical center, Dr Bastiaan de Galan  
**Project Lead:** Novo Nordisk A/S, Dr Stephen Gough  
**Project Management:** Eurice – European Research and Project Office GmbH, Caroline Schorn

**Hypo-RESOLVE Partners at a glance**

<b>Austria</b>	Medizinische Universität Graz
<b>Belgium</b>	International Diabetes Federation
<b>Denmark</b>	Nordsjællands University Hospital Hillerød Novo Nordisk A/S Syddansk Universitet
<b>France</b>	Centre Hospitalier Universitaire Montpellier
<b>Germany</b>	Eurice – European Research and Project Office GmbH (Project Management) Sanofi-Aventis Deutschland GmbH
<b>Italy</b>	Universita Degli Studi di Padova

**FOR IMMEDIATE RELEASE**

<b>Netherlands</b>	Radboud university medical center (RUMC) / Stichting Katholieke Universiteit (Coordination)
<b>Switzerland</b>	Medtronic International Trading Sarl SIB Swiss Institute of Bioinformatics Université de Lausanne
<b>United Kingdom</b>	Eli Lilly and Company Limited King's College London The Chancellor, Masters and Scholars of the University of Cambridge The University of Edinburgh The University of Sheffield University of Dundee
<b>United States</b>	Abbott JDRF International The Leona M. and Harry B. Helmsley Charitable Trust T1D Exchange

**About IMI**

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: [www.imi.europa.eu](http://www.imi.europa.eu)

**Press Contacts**

**Project Coordinator:**

Dr Bastiaan de Galan

Radboud university medical center / Stichting Katholieke Universiteit

Phone: +31 243618819

email: [bastiaan.degalan@radboudumc.nl](mailto:bastiaan.degalan@radboudumc.nl)

**Project Lead:**

Dr Stephen Gough

Novo Nordisk A/S

Contact via Media Relations Lead Mette Kruse Danielsen

Phone: +45 30793883

email: [mkd@novonordisk.com](mailto:mkd@novonordisk.com)

Press Release



International  
Diabetes  
Federation

HYPO  
RESOLVE

**FOR IMMEDIATE RELEASE**

**International Diabetes Federation:**

Sabine Dupont

International Diabetes Federation

Phone: + 353 89 708 65 65

email: [Sabine.Dupont@idf.org](mailto:Sabine.Dupont@idf.org)



innovative  
medicines  
initiative

efpia

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, International Diabetes Federation, and the Leona M. and Harry B. Helmsley Charitable Trust.